SATURDAY, SEPTEMBER 5, 2026
BREAST CANCER
Education – Learning from the Best
Chair: V. Bjelic-Radisic, S. Gipe
08.15 am
Diagnostics and Local Therapy Decisions in High Risk Genes
T. Schnitzbauer
08.25 am
Systemic Therapy Decisions in High Risk Genes
R. Bartsch
08.35 am
Breast Cancer in Men – Special Considerations
M. Reinisch
Satellite Symposium - Lilly
Chair: P. Harter
08.45 am
Welcome
P. Harter
08.50 am
High-Risk Early Breast Cancer: Tailoring Treatment Intensification to Patient Risk
S. Kümmel
09.05 am
Recurrent Ovarian Cancer: Evolving Treatment Strategies and Clinical Challenges
J. Sehouli
09.20 am
Discussion
With the kind support of Lilly Deutschland GmbH
09.30 am
Coffee Break
BREAST CANCERGYNECOLOGIC ONCOLOGY
Update on Systemic Treatment in Breast Cancer:
What is Proven, What is Coming Next?
What is Proven, What is Coming Next?
Chair: S. Kümmel, O. Gluz
10.00 am
Triple-Negative Breast Cancer – From Early to Metastatic Disease – What Should we Know?
P. Schmid
10.20 am
HER2/neu-Positive Disease – From Early to Metastatic Disease – New Algorithm
R. Bartsch
10.40 am
HR-Positive Early Breast Cancer – Escalation and De-Escalation – What is Standard?
O. Gluz
11.00 am
HR-Positive Metastatic Breast Cancer – Sequencing Challenges in Endocrine Sensitive and Endocrine-Resistant Diseases – New Algorithm
N. Harbeck
11.20 am
Live Discussion and Live Chat
S. Kümmel, O. Gluz, P. Schmid, R. Bartsch, N. Harbeck
Scientific Symposium - Daiichi Sankyo
Transforming Treatment from First Line to Early Stage
Chair: S. Kümmel
11.40 am
Redefining First-Line Standards with Established ADCs in mBC
M. Thill
12.10 pm
Unlocking New Curative Potential in HER2+ eBC
N. Harbeck
With the kind support of Daiichi Sankyo Deutschland GmbH
12.40 pm
Lunch Break
BREAST CANCER
Axilla Surgery
Chair: S. Gipe, A. S. Caudle, W. P. Weber
01.30 pm
Do We Still Need Targeted Axillary Dissection or Are We Past it?
S. Kümmel
01.50 pm
When Do We Still Need Axillary Clearance and When Radiotherapy in Light of INSEMA, SENOMAC, ACOSOGZ011 Trials
S. Gipe
02.10 pm
Omission of Sentinel Node Biopsy in Clinically Node Negative Patients: What is Standard?
A. S. Caudle
02.30 pm
Live Discussion and Live Chat
S. Gipe, A. S. Caudle, W. P. Weber, S. Kümmel
DIAGNOSTICS AND LOCAL THERAPY
Chair: J. Heil, T. Schnitzbauer, A. S. Caudle
02.45 pm
PREPEC and PRExRT Trial Results and How do They Change our Clinical Practice
W. P. Weber
03.05 pm
AI in Breast Cancer Screening: Ready for Prime Time?
U. Bick
03.25 pm
Radiation Therapy in Metastatic Disease: Is There Anything Impossible?
J. Conibear
03.40 pm
Live Discussion and Live Chat
J. Heil, T. Schnitzbauer, A. S. Caudle, W. P. Weber, U. Bick, J. Conibear
04.00 pm
End of Event
Status: July 2026, may be subject to change
